PHUSE Stakeholder Review of ISRCTN Results System Prototype
Background Overview |
---|
The International Standard Randomised Controlled Trial Number registry (ISRCTN) recently released information for public review and comment regarding the new registry they are working on, and the results system prototype is open for review until the end of September. |
Our Collective Purpose to Connect, Share, Advance |
---|
PHUSE has established itself as a key industry voice to regulatory agencies and standards organisations, including the FDA, EMA, and CDISC. We highly value these partnerships. Our global community comprises subject-matter experts from diverse areas within healthcare, and participation in this initiative presents a valuable opportunity to help shape the future of clinical trials. |
Making a Difference to Drive Forward the Clinical Trial Landscape |
---|
Building upon our successful submission to provide feedback on new guidance to accompany the MHRA’s updated clinical trials regulations and how it is written, this PHUSE project seeks to obtain and collate stakeholder feedback regarding the ISRCTN results system prototype ahead of the deadline to provide comments (PHUSE submission to ISRCTN due end of September 2025). All responses will be anonymous. There will also be opportunities throughout the review period to join an open discussion about providing flexibility in the way members share their feedback. |
Project Leads | |
---|---|
Devaki Thavarajah, Independent | |
Lucy Marks, PHUSE Senior Project Coordinator |
Current Status (Updated Quarterly) |
---|
|
Objectives & Deliverables | Timelines |
---|---|
ISRCTN feedback. | September 2025 |